MARKET SURVEY OF

RANBAXY'S
CARDIOVASCULAR
PRODUCTS
By
Ruhi Mahajan
PGDM IV-A
Roll No:53
THE INDIAN PHARMACEUTICAL
INDUSTRY

“The Indian pharmaceutical industry

is a success story providing
employment for millions and ensuring
that essential drugs at affordable
prices are available to the vast
population of this sub-continent.”
SOME OF THE LEADING
PHARMACEUTICAL COMPANIES
 COMPANY PROFILE

Ranbaxy Laboratories Limited, India's largest pharmaceutical company,

is an integrated, research based, international pharmaceutical company,
producing a wide range of quality, affordable generic medicines, trusted
by healthcare professionals and patients across geographies.
KEY STRENGTHS OF THE COMPANY
 Leadership in Novel Drug Delivery System
(NDDS) products, which offer value-added
differentiation over conventional products.
 Strong brand building capabilities, reflected in
the fact that 20 brands feature in the “Top-300
brands of the Industry” list.
 A well-built customer interface, with one of the
highest customer coverage across India, and an
excellent franchise with both Generalists &
Specialists.
 Great emphasis is placed on Knowledge
Management and Medico-marketing
initiatives such as Advisory Board Meetings, Post
Marketing Surveillance Studies and Continuous
Medical Education programs. These have resulted
in an excellent customer relationship with the
medical fraternity
 OBJECTIVE
 To know the market share of the Ranbaxy’s
Products in Cardiovascular Section.
 To know about the current products that are
giving a tough competition to Ranbaxy.
 To know about the new competitors that have
entered into the market and are trying to
capture some of it’s share.
CARDIOVASCULAR DISEASES

Cardiovascular disease (CVD), principally heart disease

and stroke, is the Nation's leading killer for both men and
women among all racial and ethnic groups.
Almost 1 million person die of CVD each year, which
adds up to 42% of all deaths.
ANTIHYPERTENSIVE DRUGS

Anti-Hypertensive Drugs are medicines that help lower blood pressure.

Purpose

Anti-Hypertensive Drugs are used to help control blood pressure in people

whose blood pressure is too high. blood pressure that stays high all the time.
is known as hypertension.
Being aware of high blood pressure and doing something to control it are
extremely important, however. Untreated, high blood pressure can lead to
diseases of the heart and arteries, kidney damage, or stroke, and can shorten
life expectancy. 

Controlling primary hypertension,, is usually a life-long commitment. Although

people may be able to reduce the amount of medicine they take as their blood
pressure improves, they usually must continue taking it for the rest of their
lives. 
RESEARCH METHODOLOGY

Objective:
 To find the market share of Ranbaxy’s Cardiovascular Products.

Type of Research:
Exploratory research

Sample element:  
Retailers and Doctors
 
Sample unit:
Retailer 

Sample extent:
South Delhi

Sample frame:
Taking list of retailers from my seniors and meeting him at his outlet.

Sampling technique:
Convenient sampling

Sample size:
450 Retailers
 
Research methods:
  Primary methods: (a)Face to face interactions (b) Questionnaire
Secondary methods: Company manuals ,Journals ,Magazines & Internet
 
Analysis technique
Microsoft Excel has been used for the statical analysis to analyze the result.
 
Limitations:
Sometime respondents refuse to cooperate and it may possible that they give biased
and dishonest answers.
Marketing Research takes time and money.
ATORVASTATIN
Atorvastatin is popularly used drug for reducing
cholesterol. The medicine is often take with a
strict dietary and exercise regime for this.
 
Q1. What are the weekly sales of the
following brands of the drug Atorvastatin?
 STORVAS
 ATORVA
 TONACT
 ATOCOR
 AZTOR
 TG-TOR
INTERPRETATION

Ranbaxy’s Storvas is the market leader here capturing 50%

of the market share then is the Atorva having 25% of the
share that is being followed by Tonact, Atocor, Aztor and TG-
Tor having11%, 7%, 5%, 2% of the market share.
Q2. What are the weekly sales of the
following brands of the drug
Atorvastatin+Ezatamibe?

 STORVAS-EZ
 LIPI-EZ

 TONACT-EZ

 TG-TOR-EZ

 ATOCOR-E

 AZTOR-EZ
INTERPRETATION

Storvas-Ez of Ranbaxy is capturing highest market

share of 53% followed by Lipi-Ez, Tonact-Ez, TG-
Tor-Ez, Atocor-E, Aztor-Ez having 25%,10%,5%, 4%
and 1% respectively.
Q3. What are the weekly sales of the
following brands of the drug Losartan?

 COVANCE
 LOSAR

 REPACE

 LOSACAR

 TOZAAR
INTERPRETATION

Losar is the market leader capturing a 32% of the share

followed by Ranbaxy’s Covance, Repace, Losacar and
Tozaar with the market share 28%, 19%,14%,7%.
Q4. What are the weekly sales of the
following brands of the drug
Losartan+HCLT?

 COVANCE-D
 LOSAR-H

 REPACE-H

 LOSACAR-H

 TOZAAR-H
INTERPRETATION

The Losar-H is the market leader here with the market share
of 32% being closely followed by Ranbaxy’s Covance-D
having 29% of the market share. Then are Repace-H,
Losacar-H, Tozar-H with a market share of 18%, 13%, 8%.
 
Q5. What are the weekly sales of the
following brands of the drug Metformin?

 RIOMET
 GLYCOMET

 GLICIPHAGE

 GLUFORMIN
INTERPRETATION

Glyciphage is the market leader with 44% share

then is Glycomet with 30% followed by Gluformin
and Riomet of Ranbaxy having only 12% and 14%
of market share.
Q6. What are the weekly sales of the
following brands of the Alphaglucoside
Market?

 VOLIX
 GLUCOBAY

 VOLIBO

 REBOSE

 MIGNAR

 MISOBIT
INTERPRETATION

Glucobay is the most selling brand with market share of

32%, Volix is having market share of 30% followed by
Volibo 25% , Mignar 11% , Mesobit and Rebose on
1% each.
Q7. What are the weekly sales of the
following brands of the drug
Olmesartan?

 OLVANCE
 OLMY

 OLMET

 OLMEZEST

 OLMESAR

 OLSAR
INTERPRETATION

Olmezest is the market leader here with a market share of

58%. Then there is Olsar with a share of 18% followed by
Olmet at 10%, Olmesar at 7%, Olmy at 6% and Olvance at
1%.
RECOMMENDATIONS AND
SUGGESTIONS
By virtue of its robust R&D environment within the company for
both drug discovery & development and for generics the
company maintained its No. 2 rank it’s a market leader in many
sections anti-infective segment but there are still some
recommendations.
During the quarter, Ranbaxy launched Olvance (Olmesartan
Medoxomil; antihypertensive), an original research product of
Daiichi Sankyo. But it has been found out during my research
that the market has still no information about the product.
Neither the doctors are prescribing this medicine nor are any of
the retailers keeping it as there is no demand coming to them.
The segment is currently dominated by Olmezest. So:
STRATEGY FOR IMPROVING THE SALE
OF OLVANCE
 Although the company is a market leader in the
Atorvastatin segment capturing more than 50%
share of it but it should be aware of the Atorva
that is closely following it. So the communication
of the Storvas too needs to be refreshed.
 Then finally in the Alphaglucoside market
specially in the Metformin and its combination the
sales are not at all satisfactory there occupying
only 7% and 11% of the total market share. So
the company needs to take care of it.
CONCLUSION
Ranbaxy is one of the leading pharma Companies in
India. Growing ahead of the market the Company has
enhanced its competitive position in the domestic market
through its focused approach. The Company maintained
its No. 2 rank in the Indian pharmaceutical market with a
5.09% market share.

In the anti-infectives segment, the Company continues to

be the market leader with 11% market share. The
Company presently has 5 of the top 30 brands in the
Indian pharmaceutical market.

Ranbaxy Endeavour to be a leader in the generics space

and also to build a strong proprietary prescriptions
business based on the Company's research outcomes.
 o u
k y
a n
T h